First-line treatment with the combination of nivolumab (Opdivo) and chemotherapy led to a statistically significant survival benefit among previously untreated patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma (EAC) versus ...
Impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.doi:10.1200/JCO.2024.42.3_suppl.334322334#Background:Nivolumab plus chemotherapy (Nivo-Chemo) is the standard treatment for advanced gastric cancer based on the results of CheckMate 649 trial and ...
Shitara K, Moehler M, Ajani, J, et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649. Presented at the 2024 Gastroi...
Shitara K, Moehler M, Ajani, J, et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up ofCheckMate649. Presented at the 2024 Gastrointes...
A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the... This study aimed to survey the use and costs of first-line chemotherapy for advanced/recurrent gastric cancer (AGC) in real-world settings...
1年生存率在纳武利尤单抗组分别为42%和51%，化疗组为24%和39%。联合治疗：与标准化疗联合使用时，...
Indicated in combination with ipilimumab for first-line treatment of metastatic NSCLC in adults whose tumors express PD-L1 (1% or greater) with no EGFR or ALK genomic tumor aberrations Nivolumab 360 mg IV every 3 weeks, PLUS Ipilimumab 1 mg/kg IV every 6 weeks ...
In CheckMate 649, first-line nivolumab plus chemotherapy prolonged overall survival versus chemotherapy in patients with advanced/metastatic non–human epidermal growth factor receptor 2 (HER2)-positive gastric/ gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC). We present explo...
OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ...
“These results continue to support nivolumab plus cabozantinib as first-line treatment for patients with advanced or metastatic RCC,” presenting author Mauricio Burotto, MD, a medical oncologist at Bradford Hill Clinical Research Center in Santiago, Chile, said in the presentation. Investigators ...